Aligos Therapeutics Inc
NASDAQ:ALGS

  • LAST PRICE
    19.1100
  • TODAY'S CHANGE (%)
    -0.6800 (-3.4361%)
  • Bid / Lots
    19.0800/ 10
  • Ask / Lots
    19.3000/ 7
  • Open / Previous Close
    20.0100 / 19.7900
  • Day Range
    19.0000
    20.3500
  • 52 Week Range
    6.7600
    30.0000
  • Volume
    128,148

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 19, 2024

  • Nov 7, 2024

  • Nov 6, 2024

      Show headlines and story abstract

    • 4:08PM ET on Wednesday Nov 06, 2024 by MT Newswires
      Companies Mentioned: ALGS
      04:08 PM EST, 11/06/2024 (MT Newswires) -- ...

    • 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: ALGS

      unanticipated events.
      Aligos Therapeutics, Inc Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, ------------------------- ------------------------ 2024 2023 2024 2023 --------- --------- --------- Revenue from Collaborations 19 2,154 311 7,329 Revenue from Customers 1,250 1,085 3,005 5,519 Operating Expenses: Research and development 16,774 15,867 54,238 50,783 General and administrative 4,626 6,443 17,669 24,195 --------- --------- --------- --------- Total operating expenses 21,400 22,310 71,907 74,978 --------- --------- --------- --------- Loss from operations (20,131) (19,071) (68,591) (62,130) Interest and other income, net 963 1,059 19,834 3,168 --------- --------- --------- --------- Loss before income tax expense (19,168) (18,012) (48,757) (58,962) Income tax expense (91) (29) (304) (825) --------- --------- --------- --------- Net loss (19,259) (18,041) (49,061) (59,787) ========= ========= ========= ========= Basic and diluted net loss per common share (3.07) (10.37) (7.84) (34.59) ========= ========= ========= ========= Weighted-average shares common stock, basic and diluted 6,272,291 1,739,847 6,258,706 1,728,282 --------- --------- --------- --------- Aligos Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands) September 30, 2024 December 31, 2023 (Unaudited) (audited) (1) Assets Current assets: Cash and cash equivalents $ 35,331 $ 135,704 Short-term investments 39,591 - Prepaid expenses and other current assets 4,900 5,380 ------------------ ----------------- Total current assets 79,822 141,084 Other assets 8,604 10,443 ------------------ ----------------- Total assets $ 88,426 $ 151,527 ================== ================= Liabilities and Stockholders' Equity Current liabilities $ 20,956 $ 23,906 Other liabilities, noncurrent 17,374 35,541 ------------------ ----------------- Total liabilities 38,330 59,447 Total stockholders' equity 50,096 92,080 ------------------ ----------------- Total liabilities and stockholders' equity $ 88,426 $ 151,527 ================== =================

    • 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
      Companies Mentioned: ALGS

      Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

      SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024.

Peers Headlines